+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Live Biotherapeutic Products and Microbiome CDMO Market Size, Share & Trends Analysis Report by Application (C. Difficile, Crohn's Disease, IBS, Diabetes), Region (North America, Europe, APAC, MEA) with Growth Forecasts, 2025-2030- Product Image
Live Biotherapeutic Products and Microbiome CDMO Market Size, Share & Trends Analysis Report by Application (C. Difficile, Crohn's Disease, IBS, Diabetes), Region (North America, Europe, APAC, MEA) with Growth Forecasts, 2025-2030- Product Image
New

Live Biotherapeutic Products and Microbiome CDMO Market Size, Share & Trends Analysis Report by Application (C. Difficile, Crohn's Disease, IBS, Diabetes), Region (North America, Europe, APAC, MEA) with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 137 Pages
  • May 2025
  • Region: Global
  • Grand View Research
  • ID: 5786691
Description Jump to:
The Live Biotherapeutic Products and Microbiome CDMO Market was valued at USD 52.37 million in 2024, and is projected to reach USD 397.49 million by 2030, rising at a CAGR of 38.50%. The market has been growing quickly in recent years, and this trend is anticipated to continue. The rising understanding of the potential advantages of live biotherapeutic products and microbiome-based therapeutics in treating various diseases, including inflammatory bowel disease, cancer, and neurological disorders, among patients and healthcare providers.

The need for CDMOs specializing in these fields is being driven by the expanding investment by pharmaceutical and biotech businesses in live biotherapeutic products and microbiome-based medicines, and this trend is anticipated to continue in the next ten years. Companies are looking for CDMOs with the skills required to develop and produce these products as the market for LBPs and microbiome-based therapeutics grows. This has resulted in the growth of the global CDMO market, with significant expansion expected in the coming years.

Due to the increasing complexity of developing these therapies, outsourcing to CDMOs is becoming an attractive option for pharmaceutical and biotech companies. For instance, in July 2023, Exeliom Biosciences, a clinical-stage biopharmaceutical company, announced a USD 26.30 million Series A funding to advance the clinical development of its therapeutic pipeline, which includes several clinical trials of EXL01. EXL01 is a novel immunotherapy with applications in infectious diseases and cancer.

Applications-based market segments have been created for live biotherapeutic products and microbiome-based therapeutics, with the C. difficile category currently dominating the market. Effective medicines are desperately required to tackle the major and expanding health issue of recurrent C. difficile infection. For instance, in October 2023, Ferring Pharmaceuticals announced two presentations at the American College of Gastroenterology’s 2023 Annual Scientific Meeting for REBYOTA. It is the first single-dose microbiome-based treatment approved by the U.S. FDA to prevent recurrent C. difficile Infection (CDI) in adults aged 18 & above following antibiotic treatment for recurrent CDI. The market for live biotherapeutic products and microbiome-based medicines is anticipated to develop since there is an increasing need for effective treatments for C. difficile and other illnesses.

The COVID-19 pandemic has significantly impacted the market for live biotherapeutic products and microbiome contract development and manufacturing organizations (CDMOs). The disruption caused by the pandemic has led to delays in clinical trials, decreased demand for certain products, and supply chain disruptions. However, with the easing of pandemic-related restrictions and the increasing focus on healthcare, the market for LBPs and microbiome-based therapies is expected to rebound in the coming years. Companies in this space will need to adapt to new challenges and find innovative solutions to maintain growth in a post-pandemic world.

Live Biotherapeutic Products And Microbiome CDMO Market Report Highlights

  • C.difficle held the largest revenue share in 2024 owing to the increasing prevalence of C.difficle infections and the growing demand for effective treatments are propelling the growth of the live biotherapeutic products and microbiome contract development and manufacturing market.
  • Many companies focus on developing and manufacturing products for treating C.difficle infections, driving the market's expansion.
  • North America live biotherapeutic products and microbiome CDMO market accounted for the largest share of 76.84% in 2024 of the global live biotherapeutic products and microbiome market.
  • Asia-Pacific is expected to grow at a CAGR of 44.82% during the forecast period. The market in Asia-Pacific has witnessed significant growth and promising developments in recent years.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates and Forecast Timeline
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Purchased Database
1.3.3. Internal Database
1.3.4. Secondary Sources
1.3.5. Primary Research
1.4. Information or Data Analysis
1.4.1. Information Analysis
1.4.2. Market Formulation & Data Visualization
1.4.3. Data Validation & Publishing
1.5. Model Details
1.5.1. Commodity Flow Analysis (Model 1)
1.5.2. Top Down Market Estimation (Model 2)
1.5.3. Value-Chain-Based Sizing & Forecasting (Model 3)
1.5.4. Multivariate Analysis (Model 4)
1.6. List of Secondary Sources
1.7. List of Abbreviations
1.8. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape
Chapter 3. Live Biotherapeutic Products And Microbiome CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. High Potential of Live Biotherapeutic Products and Microbiome in Treating Chronic & Infectious Diseases
3.2.1.2. Increase in Clinical Research on Live Biotherapeutic Products
3.2.1.3. Increasing Demand for One-Stop-Shop CDMOs
3.2.2. Market Restraint Analysis
3.2.2.1. Compliance Issues in Outsourcing
3.2.2.2. Availability of Substitutes
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Clinical Trial Volume Analysis, 2024
3.6. Industry Market Analysis Tools
3.6.1. Porter’s Five Forces Analysis
3.6.2. PESTEL Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Live Biotherapeutic Products and Microbiome CDMO Market: Application Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Live Biotherapeutic Products and Microbiome CDMO Market Application Movement Analysis
4.3. Global Live Biotherapeutic Products and Microbiome CDMO Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
4.4. C. Difficle
4.4.1. C. Difficle Market Estimates and Forecasts, 2018-2030 (USD Million)
4.5. Crohn’s disease
4.5.1. Crohn's Disease Market Estimates and Forecasts, 2018-2030 (USD Million)
4.6. IBS
4.6.1. IBS Market Estimates and Forecasts, 2018-2030 (USD Million)
4.7. Diabetes
4.7.1. Diabetes Market Estimates and Forecasts, 2018-2030 (USD Million)
4.8. Others
4.8.1. Others Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 5. Pharmaceutical Transportation Services Market: Regional Estimates & Trend Analysis
5.1. Regional Market Share Analysis, 2024 & 2030
5.2. Regional Market Dashboard
5.3. Market Size & Forecasts Trend Analysis, 2018 to 2030 (USD Million)
5.4. North America
5.4.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.4.2. U.S.
5.4.2.1. Key country dynamics
5.4.2.2. Competitive scenario
5.4.2.3. Regulatory scenario
5.4.2.4. U.S. market estimates and forecasts, 2018-2030 (USD Million)
5.4.3. Canada
5.4.3.1. Key country dynamics
5.4.3.2. Competitive scenario
5.4.3.3. Regulatory scenario
5.4.3.4. Canada market estimates and forecasts, 2018-2030 (USD Million)
5.4.4. Mexico
5.4.4.1. Key country dynamics
5.4.4.2. Competitive scenario
5.4.4.3. Regulatory scenario
5.4.4.4. Mexico market estimates and forecasts, 2018-2030 (USD Million)
5.5. Europe
5.5.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.5.2. UK
5.5.2.1. Key country dynamics
5.5.2.2. Competitive scenario
5.5.2.3. Regulatory scenario
5.5.2.4. UK market estimates and forecasts, 2018-2030 (USD Million)
5.5.3. Germany
5.5.3.1. Key country dynamics
5.5.3.2. Competitive scenario
5.5.3.3. Regulatory scenario
5.5.3.4. Germany market estimates and forecasts, 2018-2030 (USD Million)
5.5.4. France
5.5.4.1. Key country dynamics
5.5.4.2. Competitive scenario
5.5.4.3. Regulatory scenario
5.5.4.4. France market estimates and forecasts, 2018-2030 (USD Million)
5.5.5. Italy
5.5.5.1. Key country dynamics
5.5.5.2. Competitive scenario
5.5.5.3. Regulatory scenario
5.5.5.4. Italy market estimates and forecasts, 2018-2030 (USD Million)
5.5.6. Spain
5.5.6.1. Key country dynamics
5.5.6.2. Competitive scenario
5.5.6.3. Regulatory scenario
5.5.6.4. Spain market estimates and forecasts, 2018-2030 (USD Million)
5.5.7. Denmark
5.5.7.1. Key country dynamics
5.5.7.2. Competitive scenario
5.5.7.3. Regulatory scenario
5.5.7.4. Denmark market estimates and forecasts, 2018-2030 (USD Million)
5.5.8. Norway
5.5.8.1. Key country dynamics
5.5.8.2. Competitive scenario
5.5.8.3. Regulatory scenario
5.5.8.4. Norway market estimates and forecasts, 2018-2030 (USD Million)
5.5.9. Sweden
5.5.9.1. Key country dynamics
5.5.9.2. Competitive scenario
5.5.9.3. Regulatory scenario
5.5.9.4. Sweden market estimates and forecasts, 2018-2030 (USD Million)
5.6. Asia Pacific
5.6.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.6.2. Japan
5.6.2.1. Key country dynamics
5.6.2.2. Competitive scenario
5.6.2.3. Regulatory scenario
5.6.2.4. Japan market estimates and forecasts, 2018-2030 (USD Million)
5.6.3. China
5.6.3.1. Key country dynamics
5.6.3.2. Competitive scenario
5.6.3.3. Regulatory scenario
5.6.3.4. China market estimates and forecasts, 2018-2030 (USD Million)
5.6.4. India
5.6.4.1. Key country dynamics
5.6.4.2. Competitive scenario
5.6.4.3. Regulatory scenario
5.6.4.4. India market estimates and forecasts, 2018-2030 (USD Million)
5.6.5. Australia
5.6.5.1. Key country dynamics
5.6.5.2. Competitive scenario
5.6.5.3. Regulatory scenario
5.6.5.4. Australia market estimates and forecasts, 2018-2030 (USD Million)
5.6.6. South Korea
5.6.6.1. Key country dynamics
5.6.6.2. Competitive scenario
5.6.6.3. Regulatory scenario
5.6.6.4. South Korea market estimates and forecasts, 2018-2030 (USD Million)
5.6.7. Thailand
5.6.7.1. Key country dynamics
5.6.7.2. Competitive scenario
5.6.7.3. Regulatory scenario
5.6.7.4. Thailand market estimates and forecasts, 2018-2030 (USD Million)
5.7. Latin America
5.7.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.7.2. Brazil
5.7.2.1. Key country dynamics
5.7.2.2. Competitive scenario
5.7.2.3. Regulatory scenario
5.7.2.4. Brazil market estimates and forecasts, 2018-2030 (USD Million)
5.7.3. Argentina
5.7.3.1. Key country dynamics
5.7.3.2. Competitive scenario
5.7.3.3. Regulatory scenario
5.7.3.4. Argentina market estimates and forecasts, 2018-2030 (USD Million)
5.8. MEA
5.8.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
5.8.2. South Africa
5.8.2.1. Key country dynamics
5.8.2.2. Competitive scenario
5.8.2.3. Regulatory scenario
5.8.2.4. South Africa market estimates and forecasts, 2018-2030 (USD Million)
5.8.3. Saudi Arabia
5.8.3.1. Key country dynamics
5.8.3.2. Competitive scenario
5.8.3.3. Regulatory scenario
5.8.3.4. Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
5.8.4. UAE
5.8.4.1. Key country dynamics
5.8.4.2. Competitive scenario
5.8.4.3. Regulatory scenario
5.8.4.4. UAE market estimates and forecasts, 2018-2030 (USD Million)
5.8.5. Kuwait
5.8.5.1. Key country dynamics
5.8.5.2. Competitive scenario
5.8.5.3. Regulatory scenario
5.8.5.4. Israel market estimates and forecasts, 2018-2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Competition Categorization
6.2. Company Market Assessment Analysis, 2024
6.3. Company Profiles
6.3.1. Arrant Bio
6.3.1.1. Company overview
6.3.1.2. Financial performance
6.3.1.3. Service benchmarking
6.3.1.4. Strategic initiatives
6.3.2. 4D Pharma
6.3.2.1. Company overview
6.3.2.2. Financial performance
6.3.2.3. Service benchmarking
6.3.2.4. Strategic initiatives
6.3.3. Cerbios
6.3.3.1. Company overview
6.3.3.2. Financial performance
6.3.3.3. Service benchmarking
6.3.3.4. Strategic initiatives
6.3.4. Biose Industrie
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Service benchmarking
6.3.4.4. Strategic initiatives
6.3.5. Assembly Biosciences, Inc.
6.3.5.1. Company overview
6.3.5.2. Financial performance
6.3.5.3. Service benchmarking
6.3.5.4. Strategic initiatives
6.3.6. Wacker Chemie AG
6.3.6.1. Company overview
6.3.6.2. Financial performance
6.3.6.3. Service benchmarking
6.3.6.4. Strategic initiatives
6.3.7. Quay Pharmaceuticals
6.3.7.1. Company overview
6.3.7.2. Financial performance
6.3.7.3. Service benchmarking
6.3.7.4. Strategic initiatives
6.3.8. NIZO
6.3.8.1. Company overview
6.3.8.2. Financial performance
6.3.8.3. Service benchmarking
6.3.8.4. Strategic initiatives
6.3.9. Lonza
6.3.9.1. Company overview
6.3.9.2. Financial performance
6.3.9.3. Service benchmarking
6.3.9.4. Strategic initiatives
6.3.10. Inpac Probiotics
6.3.10.1. Company overview
6.3.10.2. Financial performance
6.3.10.3. Service benchmarking
6.3.10.4. Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global live biotherapeutic products and microbiome CDMO market, by Region, 2018-2030 (USD Million)
Table 4 Global live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 5 North America live biotherapeutic products and microbiome CDMO market, by country, 2018-2030 (USD Million)
Table 6 North America live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 7 U.S. live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 8 Canada live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 9 Mexico live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 10 Europe live biotherapeutic products and microbiome CDMO market, by country, 2018-2030 (USD Million)
Table 11 Europe live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 12 UK live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 13 Germany live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 14 France live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 15 Italy live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 16 Spain live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 17 Denmark live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 18 Sweden live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 19 Norway live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 20 Asia Pacific live biotherapeutic products and microbiome CDMO market, by country, 2018-2030 (USD Million)
Table 21 Asia Pacific live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 22 Japan live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 23 China live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 24 India live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 25 Australia live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 26 South Korea live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 27 Thailand live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 28 Latin America live biotherapeutic products and microbiome CDMO market, by country, 2018-2030 (USD Million)
Table 29 Latin America live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 30 Brazil live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 31 Argentina live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 32 MEA live biotherapeutic products and microbiome CDMO market, by country, 2018-2030 (USD Million)
Table 33 MEA live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 34 South Africa live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 35 Saudi Arabia live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 36 UAE live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
Table 37 Kuwait live biotherapeutic products and microbiome CDMO market, by application, 2018-2030 (USD Million)
List of Figures
Figure 1 Live biotherapeutic products and microbiome CDMO market segmentation
Figure 2 Market research process
Figure 3 Information procurement
Figure 4 Data analysis models
Figure 5 Market formulation and validation
Figure 6 Data validating & publishing
Figure 7 Commodity flow analysis
Figure 8 Market snapshot
Figure 9 Segment snapshot
Figure 10 Competitive landscape snapshot
Figure 11 Parent market outlook, 2024 (USD Billion)
Figure 12 Ancillary market outlook, 2024 (USD Billion)
Figure 13 Live biotherapeutic products and microbiome CDMO market dynamics
Figure 14 Porter’s five forces analysis
Figure 15 Live biotherapeutic products and microbiome CDMO market: PESTEL analysis
Figure 16 Live biotherapeutic products and microbiome CDMO market, by application, 2024 (USD Million)
Figure 17 Companies with affected trials, by size
Figure 18 Affected trials, by study phase
Figure 19 Clinical trial scenario (as of January 2024)
Figure 20 Live biotherapeutic products and microbiome CDMO market: Application outlook and key takeaways
Figure 21 Live biotherapeutic products and microbiome CDMO market: Application movement analysis
Figure 22 C. difficile market estimates and forecasts, 2018-2030 (USD Million)
Figure 23 Crohn's disease market estimates and forecasts, 2018-2030 (USD Million)
Figure 24 IBS market estimates and forecasts, 2018-2030 (USD Million)
Figure 25 Diabetes market estimates and forecasts, 2018-2030 (USD Million)
Figure 26 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 27 Regional market: Key takeaways
Figure 28 Regional outlook, 2024 & 2030
Figure 29 Regional outlook, key takeaways
Figure 30 North America live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 31 Key country dynamics
Figure 32 U.S. live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 33 Key country dynamics
Figure 34 Canada live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 35 Europe live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 36 Key country dynamics
Figure 37 UK live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 38 Key country dynamics
Figure 39 Germany live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 40 Key country dynamics
Figure 41 France live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 42 Key country dynamics
Figure 43 Italy live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 44 Key country dynamics
Figure 45 Spain live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 46 Key country dynamics
Figure 47 Denmark live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 48 Key country dynamics
Figure 49 Sweden live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 50 Key country dynamics
Figure 51 Norway live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 52 Asia Pacific live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 53 Key country dynamics
Figure 54 China live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 55 Key country dynamics
Figure 56 Japan live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 57 Key country dynamics
Figure 58 India live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 59 Key country dynamics
Figure 60 Australia live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 61 Key country dynamics
Figure 62 Thailand live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 63 Key country dynamics
Figure 64 South Korea live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 65 Latin America live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 66 Key country dynamics
Figure 67 Brazil live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 68 Key country dynamics
Figure 69 Mexico live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 70 Key country dynamics
Figure 71 Argentina live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 72 MEA live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 73 Key country dynamics
Figure 74 South Africa live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 75 Key country dynamics
Figure 76 Saudi Arabia live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 77 Key country dynamics
Figure 78 UAE live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 79 Key country dynamics
Figure 80 Kuwait live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 81 Market participant categorization
Figure 82 Heat map analysis
Figure 83 Market participant categorization

Companies Mentioned

The major companies featured in this Live Biotherapeutic Products and Microbiome CDMO market report include:
  • Arrant Bio
  • 4D Pharma
  • Cerbios
  • Biose Industrie
  • Assembly Biosciences, Inc.
  • Wacker Chemie AG
  • Quay Pharmaceuticals
  • NIZO
  • Lonza
  • Inpac Probiotics

Table Information

Report AttributeDetails
No. of Pages137
PublishedMay 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 52.37 Million
Forecasted Market Value ( USD ) by 2030 $ 397.49 Million
Compound Annual Growth Rate38.5%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Live Biotherapeutic Products and Microbiome CDMO - Global Strategic Business Report - Product Image

Live Biotherapeutic Products and Microbiome CDMO - Global Strategic Business Report

  • Report
  • 108 Pages
  • Global
From
Live Biotherapeutics Products and Microbe CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Live Biotherapeutics Products and Microbe CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 184 Pages
  • Global
From
Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics), Diseases (Infectious, Gastrointestinal, Endocrine & Metabolic), Type (BCT/FMT, Live Biotherapeutics), End User (Hospitals, Clinics, Long-Term Care) - Global Forecast to 2030 - Product Image

Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics), Diseases (Infectious, Gastrointestinal, Endocrine & Metabolic), Type (BCT/FMT, Live Biotherapeutics), End User (Hospitals, Clinics, Long-Term Care) - Global Forecast to 2030

  • Report
  • 291 Pages
  • Global
From
Human Microbiome Market by Product Type, Application, Indication, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Human Microbiome Market by Product Type, Application, Indication, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Microbiome Therapeutics Market by Products, Therapeutic Area, Formulation, Source, End-use, Distribution Channel - Global Forecast to 2030 - Product Image

Microbiome Therapeutics Market by Products, Therapeutic Area, Formulation, Source, End-use, Distribution Channel - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.